secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2026-06-22T12:00:17+00:00
Accession:  0001193125-26-276718
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines President R&D Steve Kelsey to retire Jan 2027; becomes senior advisor from July 2026
--------------------------------------------------------------------------------

- Steve Kelsey, M.D., president R&D, to retire effective Jan 4, 2027; will serve as senior advisor to CEO from July 1, 2026.
- Company intends to appoint Dr. Kelsey to board of directors upon retirement, subject to board approval.
- Annual meeting results: Class III directors Alexis Borisy and Mark Goldsmith elected; PwC ratified as auditor; say-on-pay approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/d123125d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-276718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer